Skip to main content

Shares of Sangamo Therapeutics  (SGMO) - Get Sangamo Therapeutics, Inc. Report  rose sharply Monday after the release of encouraging test results for a new drug to treat severe hemophilia A.

Sangamo's stock price surged 10.53% to $12.58 after a pair of patients reported no bleeding events for as long as 24 weeks - the length of the follow-up period - after treatment with investigational SB-525 gene therapy for severe hemophilia A.

"The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) activity levels," according to an announcement by Sangamo, a genomic medicine developer, and partner Pfizer  (PFE) - Get Pfizer Inc. Report , of updated results from the Phase 1/2 Alta study.

Sangamo and Pfizer said they were also seeing encouraging results from a pair of patients more recently treated, both of whom are "demonstrating FVIII activity kinetics that appear consistent with the first two patients treated in this dose cohort."

Scroll to Continue

TheStreet Recommends

The Phase 1/2 Alta study looked at a total of 10 patients, with the best results coming from the four who were given the highest doses of SB-525.

Researchers presented the test results of the new, SB-525 gene therapy treatment on July 6 at the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH), in Melbourne, Australia.

Sangamo currently faces competition from BioMarin Pharmaceutical (BMRN) - Get BioMarin Pharmaceutical Inc. Report and Spark Therapeutics (ONCE) - Get Spark Therapeutics, Inc. Report , with the two companies in Phase 3 testing with their own treatments and as a result, further along in the Food and Drug Administration process.